Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SRPT message board posts where the ticker symbol SRPT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest SRPT SEC Filings

Filings Format Description Filing Date File/Film Number
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000899140-18-000221 (34 Act)  Size: 89 KB
2018-02-14 005-54847
18611315
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001013594-18-000139 (34 Act)  Size: 62 KB
2018-02-14 005-54847
18609677
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-004834 (34 Act)  Size: 45 KB
2018-02-12 005-54847
18595526
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-000970 (34 Act)  Size: 9 KB
2018-02-12 005-54847
18594376
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001104659-18-007895 (34 Act)  Size: 157 KB
2018-02-09 005-54847
18589698
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000315066-18-000961 (34 Act)  Size: 9 KB
2018-02-09 005-54847
18588818
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000215457-18-002425 (34 Act)  Size: 13 KB
2018-01-23 005-54847
18543216
8-K  Documents Current report, items 2.02, 7.01, and 9.01
Acc-no: 0001193125-18-005667 (34 Act)  Size: 12 MB
2018-01-08 001-14895
18515858
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001104659-17-074453 (34 Act)  Size: 179 KB
2017-12-21 005-54847
171268133
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-17-063987 Size: 5 KB
2017-12-05
More SRPT SEC Filings


Related news from
Fri, 23 Feb 2018
13:07:08 +0000
See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
Short interest is high for SRPT with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting SRPT. Over the last one-month, outflows of investor capital in ETFs holding SRPT totaled $366 million.
Fri, 16 Feb 2018
13:20:00 +0000
Today’s Research Reports on Trending Tickers: Sarepta Therapeutics and Valeant Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / February 16, 2018 / U.S. markets continued to rally for the fifth consecutive day on Thursday, after being hit with a sharp correction last week. The Dow Jones Industrial Average ...
Thu, 15 Feb 2018
15:47:00 +0000
With an Eye on Biotech, Here's Today's Trading Thesis
It is important to note that watching for a reversal is much different than being short.
Wed, 14 Feb 2018
12:50:00 +0000
New Research: Key Drivers of Growth for Morgan Stanley, Novavax, Xerox, Sarepta Therapeutics, Semgroup, and Toll Brothers — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Feb. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Morgan ...
Tue, 13 Feb 2018
15:45:00 +0000
Focused on Two Sectors
If we have a little consolidating action here the buyers will start pushing again.
Mon, 12 Feb 2018
13:20:00 +0000
Today’s Research Reports on Stocks to Watch: Sarepta Therapeutics and Sage Therapeutics
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Sarepta shares closed in the red on Friday after the company's Essence study was halted in the U.K. Shares of Sage Therapeutics also closed down after announcing ...
Fri, 09 Feb 2018
17:16:26 +0000
Why Sarepta Therapeutics Inc Stock is Sliding Today
Sarepta Therapeutics Inc (NASDAQ:SRPT) stock was hit hard today after reports claim one of its studies was put on hold. According to these recent reports, Sarepta Therapeutics Inc had to put its Essence study on hold in the U.K. The reason given is that there was “one serious adverse event” that may be connected to the drugs still in testing. The hold on the project reportedly started last week and Sarepta Therapeutics Inc has been unable to resume testing due to certain rules in the U.K. However, the trail is still progressing forward in other countries.
Fri, 09 Feb 2018
17:00:12 +0000
Sarepta shares plunge on U.K. trial halt, but analyst downplays safety fears
Sarepta Therapeutics confirmed Friday that U.K. regulators have temporarily halted a late-stage trial of two drugs for the muscle-wasting diseases Duchenne muscular dystrophy after one patient experienced a serious medical issue. In a statement, Cambridge-based Sarepta (SRPT) said the patient’s medical issue “could possibly be related” to the blinded study, in which patients were given one of two drugs, called golodirsen and casimersen, or else a placebo. An independent committee reviewed the safety data and said the trial could resume, but the U.K.’s Medicine and Healthcare products Regulatory Agency, or MHRA, nonetheless ordered Sarepta to halt the study, the company said.
Fri, 09 Feb 2018
15:08:04 +0000
Sarepta stock drops 6% after report of halted trial due to 'serious adverse event'
Sarepta Therapeutics Inc. shares dropped 6% in extremely heavy morning trade Friday after a report by new analysis service EP Vantage said that the biotech had halted treatment at United Kingdom sites ...
Thu, 08 Feb 2018
13:30:00 +0000
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Developments on March 1, 2018
CAMBRIDGE, Mass., Feb. 08, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
Thu, 08 Feb 2018
11:56:00 +0000
Bringing The Human Element Full Circle Through Adaptive Ski Coaching
A biotech investor shares a few reflections on adaptive ski coaching: By bringing together his passion for the mountains with his profession as an investor in biomedical therapies, adaptive coaching completes the circle by focusing on the most important of life’s elements — the human element.
Mon, 05 Feb 2018
13:30:00 +0000
Sarepta Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 05, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
Sun, 04 Feb 2018
13:01:00 +0000
3 Boom-or-Bust Biotech Stocks to Buy in 2018
Data from trials could send these clinical-stage biotech stocks soaring or crashing.
Wed, 31 Jan 2018
23:30:00 +0000
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Jan. 31, 2018-- Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular ...
Tue, 30 Jan 2018
18:43:12 +0000
Gene therapy stocks slammed after scientist reveals safety concerns
Shares of gene therapy companies fell sharply Tuesday, after a report by a prominent scientist revealed the safety concerns that led him to resign recently from Solid Biosciences Inc.’s scientific advisory ...
Tue, 30 Jan 2018
17:32:00 +0000
[$$] Scholarly Article Proves Toxic to Gene-Therapy Stocks
Shares of AveXis and Solid Biosciences have been depressed in morning trading after the publication of an article in the medical journal Human Gene Therapy about severe toxicity in two animal species from administration of a gene therapy similar to one used by AveXis for spinal muscular atrophy, or SMA. The article was co-authored by James Wilson, director of gene therapy in the Department of Medicine at the University of Pennsylvania, who stepped down from Solid’s scientific advisory board shortly before the company’s recent initial public offering. Shares of AveXis (AVXS), a leader in gene therapy, are off $2.53, or 2%, to around $120 after touching a low of $110 earlier in the session.
Fri, 26 Jan 2018
14:23:00 +0000
Solid Biosciences Completes IPO
Solid Biosciences (SLDB) pulled off its IPO late Thursday but had to price the deal below its most recent pricing range after the company made a surprise disclosure early Thursday about a partial clinical hold involving its critical clinical trial for a gene therapy treatment for Duchenne muscular dystrophy (DMD). In its amended IPO prospectus Thursday, Solid stated the Food and Drug Administration won’t allow the company to treat patients in its initial phase 1/2 clinical trial with a high dose of the gene therapy until it resolves certain manufacturing issues. The company, in the amended filing, downplayed the development, saying that it plans to address the manufacturing issues raised by the FDA and that it doesn’t expect the “overall timing for clinical development of SGT-001 will be affected by the partial clinical hold.” SGT-001 is the DMD gene therapy.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I absolutely LOVE ValueForum, and consider this site the most important tool I have for investing and/or trading because of the incredible information at just one site. I have learned so much from reading messages posted here that I recommend to the new comer to select an area of investing that is of interest and then read those posts starting with most current. I am sure you will gain information and learn techniques that can be applied to other areas/sectors of investing. This is an 'Invaluable' forum." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards